Evidence map›Paper›PMID 42518534›Full record

ArticleFrontiers in endocrinology2026

Associations of CALLY, CLR, and CHR with all-cause mortality in patients receiving maintenance hemodialysis: a two-center retrospective cohort study.

Ying Xu, Yujian He, Yuting Liu, Yanting Liang, Guanghao Wei, Zhen Wang, Nan Hu, Lijun Luo, Hualin Ma, Xinzhou Zhang

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying Xu *Department of Hematology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Yujian He *Department of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Yuting LiuDepartment of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Yanting LiangDepartment of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Guanghao WeiDepartment of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Zhen WangDepartment of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Nan HuDepartment of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Lijun LuoDepartment of Nephrology, Huidong People's Hospital, Huizhou, Guangdong, China.
Hualin MaDepartment of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
Xinzhou ZhangDepartment of Nephrology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients undergoing maintenance hemodialysis (MHD) remain at high risk of death. Composite inflammation-related indices may capture inflammatory burden, immune status, nutritional reserve, and lipid-related protective capacity. This study evaluated the associations of the C-reactive protein-albumin-lymphocyte (CALLY) index, C-reactive protein-to-lymphocyte ratio (CLR), and C-reactive protein-to-high-density lipoprotein cholesterol ratio (CHR) with all-cause mortality in patients receiving MHD. Methods: This retrospective two-center cohort study included adult patients undergoing maintenance hemodialysis at Shenzhen People's Hospital and Huidong People's Hospital, China. Baseline data were collected between January 2017 and October 2022, and all patients were followed until death or October 2023. CALLY, CLR, and CHR were natural log-transformed and analyzed using Cox proportional hazards models, Kaplan-Meier curves, restricted cubic splines, subgroup analyses, time-dependent receiver operating characteristic curves, and sensitivity analyses after multiple imputation. Results: During a median follow-up of 36.67 months (IQR, 20.01-52.80 months), 125 patients died. In the fully adjusted Cox models, each one-unit increase in ln CALLY was associated with lower all-cause mortality risk (HR, 0.85; 95% CI, 0.77-0.94; P = 0.002), whereas ln CLR (HR, 1.19; 95% CI, 1.06-1.33; P = 0.003) and ln CHR (HR, 1.18; 95% CI, 1.07-1.31; P = 0.002) were associated with higher mortality risk. Kaplan-Meier curves showed significant survival differences across tertiles (log-rank P = 0.016, 0.012, and 0.044). Restricted cubic spline analyses showed significant overall associations (P = 0.0158, 0.0138, and 0.0301) without significant nonlinearity. The 3-year AUCs were 0.603, 0.598, and 0.563 for ln CALLY, ln CLR, and ln CHR, respectively. Sensitivity analyses yielded similar Cox regression results. Conclusions: ln CALLY, ln CLR, and ln CHR were independently associated with all-cause mortality in MHD patients and may serve as accessible markers for initial prognostic risk stratification.

Indexed as

Cholesterol, HDLC-Reactive ProteinKidney Failure, ChronicLymphocytesRenal DialysisSerum AlbuminAgedBiomarkersCause of DeathChinaFemaleHumansLymphocyte CountMaleMiddle AgedRetrospective StudiesBiomarkersCholesterol, HDLC-Reactive ProteinSerum Albuminall-cause mortalityCALLY indexC-reactive protein-to–high-density lipoprotein cholesterol ratio (CHR)C-reactive protein-to-lymphocyte ratio (CLR)maintenance hemodialysis

Identifiers

PMID42518534
PMCPMC13381296

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.